H. Hurwitz

1.6k total citations · 1 hit paper
43 papers, 1.2k citations indexed

About

H. Hurwitz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, H. Hurwitz has authored 43 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in H. Hurwitz's work include Colorectal Cancer Treatments and Studies (22 papers), Cancer Treatment and Pharmacology (20 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). H. Hurwitz is often cited by papers focused on Colorectal Cancer Treatments and Studies (22 papers), Cancer Treatment and Pharmacology (20 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). H. Hurwitz collaborates with scholars based in United States. H. Hurwitz's co-authors include Scott N. Holden, Eric Holmgren, Fairooz F. Kabbinavar, Frank A. Scappaticci, Jamey Skillings, Emily K. Bergsland, Hans Peter Gerber, Kathy D. Miller, Jia Wang and Jenny Ngai and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

H. Hurwitz

41 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab

2007 725 citations Frank A. Scappaticci, Jamey Skillings et al. JNCI Journal of the National Cancer Institute profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
H. Hurwitz United States	12	588	267	230	230	127	43	1.2k
Bart C. Kuenen Netherlands	17	519 0.9×	264 1.0×	511 2.2×	115 0.5×	132 1.0×	31	1.2k
Ulrich‐Peter Rohr Germany	15	513 0.9×	296 1.1×	285 1.2×	61 0.3×	63 0.5×	25	1.2k
Bassel Nazha United States	16	540 0.9×	235 0.9×	154 0.7×	52 0.2×	38 0.3×	70	1.1k
Ged Byrne United Kingdom	16	356 0.6×	121 0.5×	547 2.4×	97 0.4×	122 1.0×	47	1.1k
Heath B. Mackley United States	21	538 0.9×	298 1.1×	108 0.5×	49 0.2×	28 0.2×	59	1.1k
Andrea J. Bullock United States	21	1.2k 2.1×	491 1.8×	505 2.2×	74 0.3×	94 0.7×	92	2.2k
Thomas J. Saphner United States	12	1.3k 2.2×	405 1.5×	211 0.9×	105 0.5×	172 1.4×	31	1.9k
Anthony Watkinson United Kingdom	28	544 0.9×	785 2.9×	86 0.4×	126 0.5×	217 1.7×	86	2.6k
Leila T. Tchelebi United States	14	434 0.7×	363 1.4×	194 0.8×	50 0.2×	28 0.2×	45	1.0k
Gianluca Spitaleri Italy	26	1.1k 1.9×	985 3.7×	504 2.2×	67 0.3×	43 0.3×	83	2.1k

Countries citing papers authored by H. Hurwitz

Since Specialization

Citations

This map shows the geographic impact of H. Hurwitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Hurwitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Hurwitz more than expected).

Fields of papers citing papers by H. Hurwitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Hurwitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Hurwitz. The network helps show where H. Hurwitz may publish in the future.

Co-authorship network of co-authors of H. Hurwitz

This figure shows the co-authorship network connecting the top 25 collaborators of H. Hurwitz. A scholar is included among the top collaborators of H. Hurwitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Hurwitz. H. Hurwitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Martinez, Kathryn A., Víctor M. Montori, Fátima Rodríguez, et al.. (2025). Association between Exposure to Statin Choice and Adherence to Statins: An Observational Cohort Study. Medical Decision Making. 45(7). 884–891.

Hurwitz, H., et al.. (2024). Cancer Prevention for Women Experiencing Homelessness: Onsite Mammography, Navigation, and Education. JCO Oncology Practice. 20(12). 1715–1720.

Martinez, Kathryn A., Víctor M. Montori, Fátima Rodríguez, et al.. (2024). Clinician use of the Statin Choice Shared Decision-making Encounter Tool in a Major Health System. Journal of General Internal Medicine. 39(9). 1583–1589. 1 indexed citations

Hurwitz, H., et al.. (2023). Elite Feminist Adherence and Framing: Women Nobel Laureates Speak Out against Gender Inequality. Sociological Focus. 56(2). 153–171. 1 indexed citations

Hurwitz, H., et al.. (2023). Interventions that improve patient experience evidenced by raising HCAHPS and CG-CAHPS Scores: A narrative literature review. SHILAP Revista de lepidopterología. 10(1). 107–114. 4 indexed citations

Rose, Susannah, H. Hurwitz, Mary Beth Mercer, et al.. (2021). Patient Experience in Virtual Visits Hinges on Technology and the Patient-Clinician Relationship: A Large Survey Study With Open-ended Questions. Journal of Medical Internet Research. 23(6). e18488–e18488. 33 indexed citations

Hurwitz, H., et al.. (2021). Incorporating Stakeholder Perspectives on Scarce Resource Allocation: Lessons Learned from Policymaking in a Time of Crisis. Cambridge Quarterly of Healthcare Ethics. 30(2). 390–402. 12 indexed citations

Hurwitz, H., Nikhil Uppal, J. C. Bendell, et al.. (2014). Results from a Phase 2 Study of Ruxolitinib or Placebo with Capecitabine as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer: The Recap Trial. Annals of Oncology. 25. ii115–ii115. 2 indexed citations

Starodub, Alexander, Allen Lee Cohn, Hope E. Uronis, et al.. (2011). Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.. Journal of Clinical Oncology. 29(4_suppl). 513–513. 3 indexed citations

10.

Strickler, John H., Allen Lee Cohn, M. Morse, et al.. (2011). Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.. Journal of Clinical Oncology. 29(15_suppl). 3586–3586. 5 indexed citations

11.

Tebbutt, N. C., Lara Lipton, Ralph V. Boccia, et al.. (2011). The effect of motesanib treatment on the gallbladder: A randomized phase Ib study in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). e13555–e13555. 3 indexed citations

12.

Nixon, Andrew B., Mark D. Starr, Hui Pang, et al.. (2010). Use of plasma angiome to predict PFS in patients with metastatic colorectal cancer (mCRC) treated with capecitabine, oxaliplatin, and bevacizumab (XELOX-A).. Journal of Clinical Oncology. 28(15_suppl). e21009–e21009. 1 indexed citations

13.

Drouin, Michel, Christian Kollmannsberger, Hope E. Uronis, et al.. (2010). Daily administration of MGCD265 to patients with solid tumors in a dose-escalation phase I study (study 265-101).. Journal of Clinical Oncology. 28(15_suppl). 3106–3106. 1 indexed citations

14.

Altomare, Ivy, Karen Russell, Hope E. Uronis, et al.. (2010). Phase II trial of bevacizumab (B) plus everolimus (E) for refractory metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 28(15_suppl). 3535–3535. 3 indexed citations

15.

Hurwitz, H., P. LoRusso, Geoffrey I. Shapiro, et al.. (2008). 429 POSTER Phase 1 study of food effects on pharmacokinetics of brivanib alaninate in patients with advanced or metastatic solid tumors. European Journal of Cancer Supplements. 6(12). 135–135. 2 indexed citations

16.

Bendell, Johanna C., Hope E. Uronis, Mark A. Morse, et al.. (2008). Initial results of a phase II study of oxaliplatin (OX), capecitabine (CAP), bevacizumab (BV), and cetuximab (CET) in the treatment of metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 26(15_suppl). 4063–4063. 3 indexed citations

17.

Scappaticci, Frank A., Jamey Skillings, Scott N. Holden, et al.. (2007). Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab. JNCI Journal of the National Cancer Institute. 99(16). 1232–1239. 725 indexed citations breakdown →

18.

Czito, Brian G., Christopher Willett, J. C. Bendell, et al.. (2006). 158 Increased toxicity with gefitinib, capecitabine and radiation in pancreatic and rectal cancer: phase I trial results. Radiotherapy and Oncology. 78. S53–S54. 1 indexed citations

19.

Chawla, Akhil, Eric Holmgren, David Cella, et al.. (2005). Quality of life (QoL) impact of bevacizumab (BV) when combined with irinotecan + 5-FU/leucovorin (IFL) and 5-FU/leucovorin (FL) for metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 23(16_suppl). 3564–3564. 6 indexed citations

20.

Dees, E. Claire, H. Hurwitz, Afshin Dowlati, et al.. (2004). Clinical summary of 67 heavily pre-treated patients with metastatic carcinomas treated with GW572016 in a phase Ib study. Journal of Clinical Oncology. 22(14_suppl). 3188–3188. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact